Min Lee

Min Lee is the Founder, CEO & President of IPMD. Min has over 15 years of experience in the biotech industry, having previously founded HRS Global Inc. and FCI Corporation. At IPMD, they have focused on the development of the non-invasive anti-cancer agent MA8789. Persuading investors and fostering long-term relationships, they have raised $2M in funding for the company. Additionally, they have delivered technical leadership in completing in-vitro and in-vivo studies. Lee has also participated in all aspects of business development from market research and finance to operations and marketing, ensuring adherence to the company's vision.

Some of their notable achievements include completing 12 months in-vivo (mice) and in-vitro studies at QB3 Lab in UCSF, out-performing Cisplatin (a chemo drug) in in-vitro studies in stomach, colon, brain, breast, and liver cancer cell lines, and creating and manufacturing chemical compounds that exhibit strong anti-cancer properties.

Eric Ni - Chief Technology Officer, Greg Rosner - Chief Marketing Officer, and Rimma Ten - Data Director report to Min Lee.